Survival control of malignant lymphocytes by anti-apoptotic MCL-1.

Fernandez Marrero, Yuniel; Spinner, S; Jost, P J; Kaufmann, Thomas (2016). Survival control of malignant lymphocytes by anti-apoptotic MCL-1. Leukemia, 30(11), pp. 2152-2159. Nature Publishing Group 10.1038/leu.2016.213

Text Kaufmann_Fernandez_Survival control of malignant lymphocytes by antiapotic MCL.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (473kB) | Request a copy

Programmed apoptotic cell death is critical to maintain tissue homeostasis and cellular integrity in the lymphatic system. Accordingly, the evasion of apoptosis is a critical milestone for the transformation of lymphocytes on their way to becoming overt lymphomas. The anti-apoptotic BCL-2 family proteins are pivotal regulators of the mitochondrial apoptotic pathway and genetic aberrations in these genes are associated with lymphomagenesis and chemotherapeutic resistance. Pharmacological targeting of BCL-2 is highly effective in certain indolent B-cell lymphomas; however, recent evidence highlights a critical role for the BCL-2 family member MCL-1 in several lymphoma subtypes. MCL-1 is recurrently highly expressed in various kinds of cancer including non-Hodgkin's lymphoma of B- and T-cell origin. Moreover, both indolent and aggressive forms of lymphoma require MCL-1 for lymphomagenesis and for their continued survival. This review summarizes the role of MCL-1 in B- and T-cell lymphoma and discusses its potential as a therapeutic target.Leukemia advance online publication, 2 September 2016; doi:10.1038/leu.2016.213.

Interest & Impact

Downloads

6 since deposited on 09 Nov 2016
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item